You are here
STOP 2G-TKI Study
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
Elsevier Global Medical News. 2011 Jun 30, S Freeman
2011 Jun 30, S Freeman
LONDON (EGMN) - Stopping treatment with dasatinib and nilotinib might be safe in chronic myeloid leukemia patients who have achieved sustained and complete molecular responses, early data from a pilot study have shown.
The STOP 2G-TKI study is a successor to the STop IMatinib (STIM) trial, which showed that stopping treatment with imatinib - the first-generation tyrosine kinase inhibitor (TKI) of BCR-ABL - could be feasible in patients who achieve long-lasting complete molecular responses (Lancet Oncol.2010;11:1029-35). more......